Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 282 versus GADAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 282 versus GADAVIST.
ANGIOVIST 282 vs GADAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Gadovist (gadobutrol) is a macrocyclic gadolinium-based contrast agent (GBCA) that enhances MRI signal intensity by shortening T1 relaxation time in tissues with altered vascularity or blood-brain barrier integrity.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
0.1 mmol/kg (0.2 mL/kg) IV bolus; maximum dose 0.3 mmol/kg per imaging session.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Plasma terminal elimination half-life is approximately 1.5 hours in patients with normal renal function (GFR >60 mL/min/1.73m²). In renal impairment (GFR <30 mL/min/1.73m²), half-life extends to 10-15 hours; in end-stage renal disease, half-life may exceed 30 hours, necessitating adjustment of imaging timing.
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Primarily renal; approximately 95% of administered dose excreted unchanged in urine within 72 hours, with 85% eliminated within 6 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Agent
Contrast Agent